Certara has announced that it has acquired Analytica Laser, a global research consultancy that uses health economics and outcomes research (HEOR) and real-world data to provide scientific evidence of the value of medicines and health technologies.
Analytica Laser employs cutting-edge quantitative methodologies and proprietary software to study and predict real-world outcomes for drug value assessment. The company integrates its sophisticated analytics, advanced pharmaco-epidemiology, pharmaco-economics, modeling and data science expertise, public health intelligence, and extensive experience to advise on pricing and market access strategy.
“Achieving regulatory approval alone no longer determines a drug’s or therapy’s commercial success, or even guarantees its market launch,” said Thomas Kerbusch, PhD, President of Certara Strategic Consulting Services. “Today, each product must be evaluated from a value perspective by payors and health authorities in order to be placed on the formulary, factored into reimbursement rates, and put into treatment plans before it is available for healthcare providers to prescribe.”